MétaCan
Menu
Back to cohort
Record W2086789132 · doi:10.1210/jc.2006-0656

Growth Hormone Treatment and Risk of Second Neoplasms in the Childhood Cancer Survivor

2006· article· en· W2086789132 on OpenAlexafffund
Berrin Ergun-Longmire, Ann Mertens, Pauline Mitby, Jing Qin, Glenn Heller, Weiji Shi, Yutaka Yasui, Leslie L. Robison, Charles A. Sklar

Bibliographic record

VenueThe Journal of Clinical Endocrinology & Metabolism · 2006
Typearticle
Languageen
FieldMedicine
TopicChildhood Cancer Survivors' Quality of Life
Canadian institutionsUniversity of Alberta
FundersChildren's Hospital of PittsburghHospital for Sick ChildrenUniversity of AlbertaChildren's National HospitalUniversity of California, Los AngelesMemorial Sloan-Kettering Cancer CenterUniversity of MinnesotaCincinnati Children's Hospital Medical CenterUniversity of WashingtonNational Cancer InstituteStrongEmory UniversitySchool of Medicine, Stanford UniversitySt. Jude Children's Research HospitalGenentechChildren's Hospital Los AngelesChildren's Hospital of PhiladelphiaNational Institutes of HealthChildren's Hospitals and Clinics of MinnesotaGenentech Foundation
KeywordsMedicineContext (archaeology)Internal medicineRetrospective cohort studyCohortCancerCohort studyChildhood cancerConfidence intervalProportional hazards modelPediatricsEndocrinologyBiology

Abstract

fetched live from OpenAlex

CONTEXT: GH deficiency is common in childhood cancer survivors. In a previous report, although we did not find an increase in the risk of disease recurrence in survivors treated with GH, GH-treated survivors did have an increased risk of developing a second neoplasm (SN) (rate ratio, 3.21). OBJECTIVE: In this analysis, we have reassessed the risk of GH-treated survivors developing an SN after an additional 32 months of follow-up. DESIGN AND SETTING: We conducted a retrospective cohort multicenter study. PATIENTS: Among a total of 14,108 survivors who were enrolled in the Childhood Cancer Survivor Study, a retrospective cohort of 5-yr survivors of childhood cancer, we identified 361 who were treated with GH. MAIN OUTCOME: We assessed the risk of developing an SN. RESULTS: During the extended follow-up, five new SN developed in survivors treated with GH, for a total of 20 SN, all solid tumors. Using a time-dependent Cox model, the rate ratio of GH-treated survivors developing an SN, compared with non-GH-treated survivors, was 2.15 (95% confidence interval, 1.3-3.5; P < 0.002). Meningiomas were the most common SN (n = 9) among the GH-treated group. CONCLUSION: Although cancer survivors treated with GH appear to have an increased risk of developing SN compared with survivors not so treated, the elevation of risk due to GH use appears to diminish with increasing length of follow-up. Continued surveillance is essential.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.034
GPT teacher head0.358
Teacher spread0.324 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations274
Published2006
Admission routes2
Has abstractyes

Explore more

Same venueThe Journal of Clinical Endocrinology & MetabolismSame topicChildhood Cancer Survivors' Quality of LifeFrench-language works237,207